2 1 Shi Ji Jing Ji Bao Dao·2026-01-07 14:57分组1 - Heng Rui Medicine's innovative drug Ruilafup α injection has been approved for market launch, with no similar products approved domestically or internationally [1] - The drug is used in combination with fluorouracil and platinum-based drugs for first-line treatment of locally advanced unresectable, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma with confirmed PD-L1 positivity (CPS≥1) [1] - The total R&D investment for Ruilafup α injection has reached approximately 711 million yuan [1] 分组2 - Cheng Jian Development reported that its investment in Century Space is currently in a loss state, with no unrecognized revenue impacting its operations [2] - Zhongke Lanyun expects a significant net profit increase of 366.51% to 376.51% for 2025, driven by substantial fair value changes from investments in Moer Thread and Muxi Co., Ltd [2] 分组3 - Nanjing Panda stated that it currently has no mature products related to brain-computer interfaces and has not generated related sales revenue [3] - Kecuan Technology's subsidiary has established optical module production capacity, and silicon photonic chips have completed their first tape-out but have not yet generated revenue [3] 分组4 - Zhuhai Ming Technology's subsidiary has been allocated 66,900 H-shares of Zhihua, amounting to 7.7738 million Hong Kong dollars [4] - Chengdi Xiangjiang announced that the revenue from the construction of two data center buildings will decrease by approximately 1.092 billion yuan due to changes in business conditions [4]